Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | TP53 | P04637 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 8/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466726 | 0.94 | MAPT (0.36) | MAPTTP53LMNASMN1; SMN2TDP1 | |
| SCHEMBL3487200 | 0.91 | DHODH (0.40) | TP53LMNADHODHTSHRKMT2A | |
| SCHEMBL3487199 | 0.84 | DHODH (0.39) | TP53LMNADHODHKDM4ETSHR | |
| SCHEMBL3489093 | 0.84 | KDM4E (0.42) | MAPTSMN1; SMN2KDM4EMEN1HTT | |
| SCHEMBL3486976 | 0.82 | ADORA2B (0.40) | MAPTTP53LMNADHODH | |
| SCHEMBL3489097 | 0.76 | KDM4E (0.41) | MAPTSMN1; SMN2TDP1KDM4EMEN1 | |
| SCHEMBL3486973 | 0.76 | ADORA2B (0.39) | MAPTTP53DHODHKDM4E | |
| SCHEMBL4486723 | 0.70 | BTK (0.36) | MAPTLMNASMN1; SMN2DHODHKDM4E | |
| SCHEMBL3488251 | 0.69 | CA12 (0.44) | MAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL3488399 | 0.69 | NR1H2 (0.55) | MAPTLMNASMN1; SMN2TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MAPT 1938/4885TP53 4325/4885LMNA 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.